Table 3 Timing of use with regards to administration route categories, cannabis sub-types, and cannabinoids
From: A mixed methods analysis of cannabis use routines for chronic pain management
AM | PM | Afternoon | As needed | Throughout the day | Uncertain | Total | |
|---|---|---|---|---|---|---|---|
Subgroups | |||||||
Inhalation | 146 (10.8%) | 496 (36.7%) | 71 (5.3%) | 211 (15.6%) | 337 (24.9%) | 91 (6.7%) | 1352 |
Non-inhalation | 210 (19.4%) | 377 (34.7%) | 63 (5.8%) | 168 (15.5%) | 160 (14.7%) | 107 (9.9%) | 1085 |
Cannabis subtypes | |||||||
Indica | 6 (2.7%) | 177 (80.8%) | 5 (2.3%) | 13 (5.9%) | 11 (5.0%) | 7 (3.2%) | 219 |
Sativa | 46 (32.2%) | 10 (7.0%) | 14 (9.8%) | 14 (9.8%) | 53 (37.1%) | 6 (4.2%) | 143 |
Hybrid | 4 (6.5%) | 19 (30.6%) | 11 (17.7%) | 5 (8.1%) | 19 (30.6%) | 4 (6.5%) | 62 |
Cannabinoids | |||||||
CBD | 128 (27.3%) | 100 (21.3%) | 31 (6.6%) | 56 (11.9%) | 118 (25.2%) | 36 (7.7%) | 469 |
THC | 44 (12.0%) | 179 (48.9%) | 15 (4.1%) | 49 (13.4%) | 59 (16.1%) | 20 (5.5%) | 366 |
1:1 CBD:THC | 15 (21.1%) | 20 (28.2%) | 8 (11.3%) | 8 (11.3%) | 18 (25.4%) | 2 (2.8%) | 71 |
Unknown cannabinoids | 184 (13.3%) | 504 (36.3%) | 82 (5.9%) | 219 (15.8%) | 278 (20.0%) | 121 (8.7%) | 1388 |